16th ANNUAL MEETING & DINNER
NATIONAL ALLIANCE OF STATE PROSTATE CANCER COALITIONS

“PARTICIPATE AND EDUCATE”

January 28 - 30, 2022
Hotel Monaco, Washington, D.C.
WELCOME TO
THE 16TH ANNUAL MEETING!

Friday through Sunday
January 28 - 30, 2022

On behalf of the leadership of the National Alliance of State Prostate Cancer Coalitions (aka "THE PROSTATE CANCER ALLIANCE"), I would like to welcome you to the long-postponed 16th Annual Meeting delayed to now, January 28-30, 2022!

A huge thanks to our esteemed faculty members who traveled to this Hotel this weekend to help us learn, to share their knowledge and expertise, and to enter into advisory and friend relationships with so many of the attendees, all of whom braved the elements, including COVID, to attend and participate. Some faculty were unable to travel but we are grateful that they agreed to share their presentations remotely.

We hope this will once again be a valuable weekend of education, of sharing and learning about best practices, of participation, and of networking. The creative energy and enthusiasm that comes from an in-person Meeting cannot be over-emphasized. Our Annual Meeting is unique in that respect.

Another huge thank you to our many sponsors who recognize the importance of our unique Annual Meeting and who value the work of our Alliance. There is a page dedicated to them in this Meeting Brochure and their names appear on various materials you will see here at the 16th Annual Meeting.

If you have any questions, please don’t hesitate to contact our Vice President, LaTanya Patton (Missouri); our Director-at-Large Donald Lynam (Kentucky); our Steering Committee Chair, Tom Kirk (California), or me (California as well). And thanks to our tireless staff person, Tiffany Razzo and her husband George I(Texas), without whom we could not have organized this Annual Meeting, and whom we will miss this weekend.

Respectfully,

Merel Grey Nissenberg,
President, “The Prostate Cancer Alliance” (NASPCC)
# 16th ANNUAL MEETING
**NATIONAL ALLIANCE OF
STATE PROSTATE CANCER COALITIONS**

**“PARTICIPATE AND EDUCATE”**

**FRIDAY JANUARY 28, 6:00 PM - 9:00 PM RECEPTION IN THE GLASS HOUSE, DIRTY HABIT RESTAURANT, HOTEL MONACO**

**SATURDAY, JANUARY 29, ALL SESSIONS ARE IN THE PARIS ROOM, HOTEL MONACO**

## AGENDA

<table>
<thead>
<tr>
<th>SESSION NAME</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breakfast</td>
<td>8:00 – 8:45</td>
</tr>
<tr>
<td><strong>I. THE BASICS</strong></td>
<td></td>
</tr>
<tr>
<td>1. Introduction and Welcome</td>
<td>9:00-9:10</td>
</tr>
</tbody>
</table>
| 2. Prostate Cancer 101: | 9:10-9:35 | *Vincent Laudone, MD*  
Memorial Sloan Kettering, New York |
| 3. Prostate Cancer Genetics | 9:35-10:00 | *Atish Choudhury, MD*  
Dana Farber (Harvard), Boston |
| 4. Critical Aspects of Prostate Cancer Pathology | 10:00-10:40 | *Jonathan Epstein, MD*  
Johns Hopkins, Baltimore |
| 5. The ABC's of Androgen Deprivation Therapy and Anti-Androgens | 10:40-11:10 | *Mark Markowski, MD*  
Johns Hopkins;  
*Michael Morris, MD*  
Memorial Sloan Kettering |
| MORNING BREAK | 11:10-11:15  |
| **II. TREATMENT OF DISEASE BASED ON RISK ASSESSMENT** |           |
| 6. Risk Assessment of Disease for Treatment Planning | 11:15-11:45 | *Vincent Laudone, MD*  
Memorial Sloan Kettering |
| 7. Basics of Prostate Cancer-Immuno-Oncology and Immuno-Therapeutics | 11:45-12:15 | *Saul Priceman, PhD*  
City of Hope, Los Angeles, California and Immuno-oncologists in the Audience |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15-1:00</td>
<td>LUNCH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:05-1:30</td>
<td>8. Imaging Agents, The Role of PSMA Lutetium, Theranostics and Radioligand Therapy</td>
<td>*Michael Morris, MD</td>
<td>Memorial Sloan Kettering</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30-2:05</td>
<td>9. Low Risk Localized PCa: Genomic Tests, Focal Treatment and Active Surveillance</td>
<td>*Vincent Laudone, MD</td>
<td>Memorial Sloan Kettering</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daniel Song, MD</td>
<td>Johns Hopkins</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:05-2:40</td>
<td>10. Multimodal Therapy for Intermediate and High Risk Disease</td>
<td>*Vincent Laudone, MD</td>
<td>Memorial Sloan Kettering</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Andrew Armstrong, MD, MSc</td>
<td>Duke University</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:45-3:05</td>
<td>11. Imaging and Theranostics: Thera-P and VISION Trials</td>
<td>*Michael Morris, MD</td>
<td>Memorial Sloan Kettering</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:05-3:20</td>
<td>III. A SYSTEMATIC APPROACH TO SYSTEMIC THERAPY</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12. Precision Medicine in Advanced Prostate Cancer; Chemotherapy Options</td>
<td>*Andrew Armstrong, MD, MSc</td>
<td>Duke University</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:20-3:55</td>
<td>13. Untreated Metastatic Prostate Cancer</td>
<td>*Mark Markowski, MD</td>
<td>Johns Hopkins</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:55-4:10</td>
<td>AFTERNOON BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:10-4:40</td>
<td>15. Biochemical/PSA Recurrence of Prostate Cancer</td>
<td>*Ashley Ross, MD, PhD</td>
<td>Northwestern Memorial Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:40-5:00</td>
<td>16. Updates in Management of Men Newly-Diagnosed with Metastatic Prostate Cancer</td>
<td>*Andrew Armstrong, MD, MSc</td>
<td>Duke University</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:05-5:25</td>
<td>17. Treatment of DNA Repair-Deficient Prostate Cancer</td>
<td>*Emmanuel Antonarakis, MD</td>
<td>U of Minnesota</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADJOURN *****</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dinner starts at 6:30 P.M.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paris Room, Hotel Monaco</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SUNDAY, JANUARY 30

**AGENDA**

**SESSION NAME** | **TIME** | **TIME**
--- | --- | ---
Breakfast | 8:00-8:45 | Mark Vieth, CRD Associates
Current Update on the CDMRP and DOD Research Funding | |

**IV. OPTIMIZING NASPCC: HOW CAN WE HELP STATES AND PATIENTS?**

19. PROSTATEPEDIA Magazine and DIGEST — Going Forward | 9:50-10:00 | *Jessica Myers-Schecter

20. “My Story” | 10:05-10:20 | *Brian McCloskey
21. Patient Navigators | 10:20-10:35 | *Cara Clements
22. PROMISE Registry | 10:35-10:50 | *Jenny Chiang

**ELECTIONS for 2022 Officers and Board** | 10:50-11:10 | Jan Marfyak, Secretary

**BREAK** | 11:10-11:15 | |

**V. FROM THE PATIENT’S PERSPECTIVE**

23. How to Approach Decision-Making: Medical and Patient Perspectives | 11:15-11:45 | *Michael Zaragoza, MD
*Dave Hulbert, *Bruce Williams *Brian McCloskey

24. Report from the Chair of STEERING COMMITTEE | 11:45-12:15 | *Thomas Kirk, Chair and Advisory Committee Chairs

**LUNCH** | 12:15-1:00 | |

25. What Lies Ahead for NASPCC? A New 5-Year STRATEGIC PLAN | 1:00-2:15 | *LaTanya Patton and Attendees’ Discussion

26. Wrap Up; Calendaring and Conclusions | 2:15-3:00 | *Merel Nissenberg

---

**ADJOURN** | 3:00 p.m. | |
ABOUT NASPCC – “THE PROSTATE CANCER ALLIANCE”

The National Alliance of State Prostate Cancer Coalitions (NASPCC) is a 501(c)(3), not-for-profit organization, with an extensive network and national outreach through many state prostate cancer organizations and individuals. We are an Alliance comprised of many entities, including state prostate cancer coalitions, foundations, associations, and others who are interested in helping to save the lives of men with prostate cancer.

NASPCC – “The Prostate Cancer Alliance” was formed in October 2004 to serve as an umbrella organization in which state prostate cancer organizations could participate and help generate “strength in numbers”. We have become a large critical mass and voice for prostate cancer patients and their families.

We publish PROSTATEPEDIA Magazine (8 times a year) and a weekly PROSTATEPEDIA DIGEST, a compendium of the most current curated articles, abstracts, and press releases. Subscriptions are free and these are sent to 12,000+ people on our Subscription List. The Magazines are archived on our www.naspcc.org website.

We advocate for Informed Decision-Making in prostate cancer, and we disseminate durable, laminated 2-sided education tools for both patients AND for physicians. There are 5 completed Laminates and 5 in queue. See www.prostatecaif.org/patient-guide. We hold an Annual Meeting to enhance education and to share best practices with patients across the country. The resources we disseminate make their way through to the states and reach down through to the local levels, including support groups and individuals who do not participate in those groups.

We actively provide, through our participating organizations: support groups, educational forums, Webinars, Workshops, prostate cancer information, and awareness and educational activities. Our website www.naspcc.org is very dynamic and we have an active Facebook Page “National Alliance of State Prostate Cancer Coalitions” as well.

We advocate for the highest quality of life for prostate cancer patients and their families.
We have an Advisory Board comprised of influential and respected physicians, scientists and researchers.
We are many states strong and growing. We are “The Prostate Cancer Alliance”!

EDUCATIONAL OBJECTIVES

At the conclusion of NASPCC’s 16th Annual Meeting & Gala, attendees should be aware of the basics of prostate cancer; fundamentals of testing (genetic, genomic and other tests and imaging); critical aspects of prostate cancer pathology; risk assessment for treatment planning; fundamentals of treatment for different stages of prostate cancer; new developments in molecular imaging with PSMA; fundamentals of Low-Risk Disease, Focal Therapy, and Active Surveillance; Advanced and untreated metastatic disease, as well as non-metastatic castrate-resistant disease; fundamentals of immunotherapy; fundamentals of recurrence; and how to ensure that patients have appropriate access to optimal care, whether they are treated at an academic center or in a community setting. This information should then enable patients – and those that help them make treatment choices – to make informed, individualized decisions with their physicians.
Prostatepedia features informal conversations with doctors, patients, and activists about prostate cancer. Each issue tackles a different topic facing prostate cancer patients today—from how imaging has impacted treatment to dealing with erectile dysfunction after radiation or surgery to the evolving field of immunotherapy.

Prostatepedia Magazine (eight times a year) and the weekly Prostatepedia Digests became part of NASPCC starting with the August 2020 Issue of the magazine.

Use the links below to view/read each issue on the user-friendly “flipping book” page. If you would prefer to download and print out your copy of the issue, use the link on that issue’s page to download a PDF version.

December 2021 - *Immuno-Oncology and Chemotherapy*
Prostatepedia Magazine - Vol 6 No. 6 - Flipping Book format:
https://online.flippingbook.com/view/121290624/

September 2021 - *Chemotherapy*
Prostatepedia Magazine - Vol 6 No. 5 - Flipping Book format:
https://online.flippingbook.com/view/485103127/

June 2021 - *Imaging*
Prostatepedia Magazine - Vol 6 No. 4 - Flipping Book format:
https://online.flippingbook.com/view/494745542/

March 2021 - *Testing*
Prostatepedia Magazine - Vol 6 No. 3 - Flipping Book format:
https://online.flippingbook.com/view/824949921/

November 2020 - *Immuno-Oncology and PARP Inhibition*
Prostatepedia Magazine - Vol 6 No. 2 - Flipping Book format:
https://online.flippingbook.com/view/542030/

August 2020 - *Chemotherapy*
Prostatepedia Magazine - Vol 6 No. 1 - Flipping Book format:
https://online.flippingbook.com/view/193912/3/

Please use this link to Subscribe to Prostatepedia:
https://mailchi.mp/c98f8914f351/prostatepedia-sign-up


NATIONAL ALLIANCE
OF
STATE PROSTATE CANCER COALITIONS

EXECUTIVE COMMITTEE

Merel Nissenberg, Esq. (California)
President, National Alliance of State Prostate Cancer Coalitions
Merel Grey Nissenberg, Esq, is a medical malpractice attorney in Los Angeles handling cases around the country, and she is President of three non-profits in healthcare: the National Alliance of State Prostate Cancer Coalitions (NASPCC); the California Prostate Cancer Coalition (CPCC), both of which she co-founded; and the Clifton F. Mountain Foundation for Education & Research in Lung Cancer. She is a member of two National Cancer Institute SPORES (one in Prostate Cancer at UCLA, one in Lung Cancer at M. D. Anderson Cancer Center), and she is on the UCLA SPORE Executive Committee. She is also the Advocate for the Canary Foundation/PASS Trial at Stanford (Prostate Active Surveillance) and is part of a PCORI Grant with UCLA dealing with decision aids in prostate cancer. Additionally, through her consulting group Informed Health Consulting she and her partner help accrue patients to Clinical Trials and also create Patient Ambassador Programs and Roundtables. Merel has been actively involved for almost ten years as one of three national Patient Advocates for the Early Detection Research Network (EDRN) of the National Cancer Institute, handling three of the four Collaborative Groups: GU Cancers, GYN Cancers, and Lung Cancer. In her law practice she has represented many cancer patients and has advocated for them and for their families. Merel is extremely interested in the early detection of cancers when they are still curable and is dedicated to improving the lives of patients, including those as-yet-undiagnosed.

Anthony Minter (South Carolina)
Treasurer, National Alliance of State Prostate Cancer Coalitions
Anthony Minter has been involved with Prostate Cancer Advocacy since 2012. As a Survivor, he made it his mission to provide support, education and awareness within his community and throughout the nation. Tony is the leader of the Columbia Chapter of UsToo International and a Consumer Advocate for Zero Prostate Cancer. He is also on the Board of Directors of the South Carolina Cancer Alliance. Recently, he has been selected to serve on the Executive Board of the National Alliance of State Prostate Cancer Coalitions (NASPCC) and is the current treasurer. He has participated in numerous health fairs and information sessions concerning prostate cancer and has been a key link between the patients, their families and their physician. He is a Certified Professional Executive Coach, specializing in Relationships, Leadership, Career and life. Tony was also selected to be a Consumer Reviewer for the Congressionally Directed Medical Research Program (CDMRP), responsible for screening applications for research grants aimed at finding new treatment therapies, creating better detection tools and decreasing the Prostate Cancer health disparity in men of African descent.

Jan Marfyak (New Mexico)
Secretary, National Alliance of State Prostate Cancer Coalitions
Jan Marfyak is one of the founders of NASPCC, served as its Treasurer, and is currently Secretary. He has been on the Board of Directors since 2004, the year of its organization. Jan served in Wisconsin State government after leaving the University of Wisconsin, and later moved to Washington DC, first at the Department of Justice and later at the Department of Energy. He is a prostate cancer survivor (1975) and is Secretary of the Prostate Cancer Support Association of New Mexico, an active state prostate cancer organization.

Following treatment, Jan volunteered at the Foundation for Urological Disease in Baltimore, MD and later started the Pennsylvania State Prostate Coalition. Jan has been instrumental in helping to start other state prostate cancer organizations and in sharing his knowledge of budget and advocacy issues.

Donald Lynam, PhD (Kentucky)
Director at Large, National Alliance of State Prostate Cancer Coalitions
Don has been active in the prostate cancer community for approximately 20 years, with NASPCC, and before that, Us TOO. He has served on the Board of Directors (BOD), Executive Committee, and Treasurer of NASPCC for the past 9 years. Don is Vice Chairman of KY PCC. He is a past member and Vice Chairman of the BOD of Us TOO, and Chapter Leader of Us TOO of the Bluegrass (Lexington, KY) for the past 15 years.

Don has degrees in Engineering (B.S. and M.S.) from the University of Kentucky and Environmental Health (M.S. and Ph.D.) from the University of Cincinnati. He served 3 years in the US Air Force, as a commissioned officer, primarily at the US Air Force Flight Test Center and Rocket Propulsion Laboratory at Edwards AFB in California. He spent a successful career in the metals and petroleum chemicals industry in engineering and environmental health, retiring as Corporate Vice President.

LaTanya Patton (Missouri)
Vice President, National Alliance of State Prostate Cancer Coalitions
LaTanya currently serves as the President and CEO of Missouri Prostate Cancer Alliance (MoPCA) which she co-founded 2013. In addition to her professional work, she is the primary caregiver for her mother who is stricken with Alzheimer’s disease. LaTanya is a brain aneurysm survivor and supports the University of Missouri. continued on next page
LaTanya Patton continued
Kansas Health System Brain Aneurysm support group.

Prior to Missouri Prostate Cancer Alliance, she worked for Blue Cross and Blue Shield of Kansas City; Heart to Heart International – assigned to the country of Haiti; served as President and CEO of a small minority agency; Vice-President of Community Relations of MAST Ambulance and worked in various capacities for the City of Kansas City Missouri for 16 years including the Health Department before leaving to furthering her professional career.

LaTanya’s community service activities include serving as an Ambassador for American Heart Association, The Mayor’s Commission on AIDS/HIV (TGA), Ivy Community Service and Education Foundation, Swope Ridge Geriatric Center Board of Directors. She serves on the Board of Directors of NASPCC - Director at Large. LaTanya has been an active member of Alpha Kappa Alpha Sorority Incorporated for 34 years and is the immediate past President her chapter.

LaTanya has earned a Bachelor of Science in Business Administration from Lincoln University, Jefferson City, Missouri and is pursuing a Master in Business Administration from the University of Phoenix with an emphasis in organizational development and non-profit leadership. In addition, LaTanya considers herself a consistent leaner and is completing a teaching certification program at Western Bible College in Christian Education.

She has been a devoted member of her church in Kansas City, Missouri for the past 35 years where she serves as Culinary Leader, Youth Director and Vacation Bible School Director. She wants you to know that she is a “CHILD OF THE KING.” She has received numerous awards and recognitions.

LaTanya is happily married to Frederick Patton and has two beautiful daughters, Lauren Patton, and Logan Patton. In her spare time, she enjoys reading, shopping, participating community service activities with the sorority, volunteering and traveling with her family.

Thomas Kirk
Invited Member, National Alliance of State Prostate Cancer Coalitions

Tom Kirk has been heavily involved in Patient Advocacy Non-Profit Organizations. He currently serves as the Vice-President of the California Prostate Cancer Coalition (CPCC), which is “A Proud Participant in the National Alliance of State Prostate Cancer Coalitions” (NASPCC). Tom is also an Invited Member of the NASPCC Executive Committee.

Tom Kirk developed the Strategic Plan for NASPCC in 2017 and as Chair of NASPCC’s Steering Committee, he monitors the Plan’s implementation with the NASPCC Committees that were created to move it forward. Tom also serves on the NASPCC Advocacy and Public Policy Committee which, following NASPCC’s 2018 Bone Health Access Initiative (BHI), and the October Bone Health Access Roundtable, prioritized “Step Therapy and Access” as an issue.

In prostate cancer, Tom served as the President and CEO of Us TOO International in suburban Chicago for over 10 years, before moving to California in 2016. He currently works as a Co-Founder of Informed Health Consulting (IHC).

Additionally, Tom worked for over 12 years at the National Alzheimer’s Association headquartered in Chicago. He worked on the Senior Management Team where he was the Vice President of Patient, Family and Education Services. He has also assisted other Residential Care Providers (Mather Life Ways and Belmont Village) develop their Dementia Care Services, and he worked as the Vice President of Operations for Life Care Centers of America’s Garden Terrace Associates managing their specialized Dementia-Specific Long-Term Care Centers and Dementia Care Units. Tom holds an MSSW Degree in Planning and Administration from the University of Wisconsin-Madison.

BOARD OF DIRECTORS 2020-2021

Mary Anderson – North Carolina
Dave Hulbert – Minnesota
Crissy Kantor – New Hampshire
Paul Kradel – West Virginia
Robin Leach – Texas
Harold Pharoah – Nebraska
Stephen Richardson – Utah
Gabe Rosko – New Jersey
David Sauls – Delaware
Renee Savickas – Colorado
Bruce Williams – Arizona
Clarence Williamson – Tennessee
Ullyses Wright – Kansas
“Reaching Thousands of Prostate Cancer Patients and their Families Across the U.S. Since 2004”

MISSION STATEMENT

NASPCC is a nation-wide organization, comprised of state prostate cancer coalitions, dedicated to saving men’s lives and enhancing the quality of life of prostate cancer patents and their families, through awareness and education and the development of a public policy network.

LEADERSHIP

NASPCC has an elected Board of Directors made up of State Representatives, which meets four times a year; and a Standing Executive Committee which meets monthly, composed of the four Officers, an elected Director-at-Large and an Invited Member. Eight Advisory Committees were formed in November 2017 to help accomplish the goals of the Strategic Plan adopted in July 2017. In September 2018, the Executive Committee created a Standing Committee, chaired by Tom Kirk, to monitor and strengthen the progress of these Eight Advisory Committees:

- Advocacy and Public Policy, Chair: Donald Lynam/Alvin Chin (deceased)
- Annual Meeting Committee, Chair: Merel Grey Nissenberg
- Budget Committee, Chair: Donald Lynam
- Communications Committee, Chair: Renee Savickas/Fran Franklin
- Education and Awareness Committee, Chair: Fran Franklin/Clarence Williamson
- Fundraising Committee, Chair: Merel Grey Nissenberg
- Medical Advisory Committee, Chair: Michael Zaragoza, MD
- State Coalition Development Committee, Chair: Ira Baxter/Robert Johnson

REACHING PATIENTS AND THEIR FAMILIES

NASPCC supports the development of state prostate cancer organizations, each of which is comprised of patient networks and support groups. NASPCC through its Annual Meeting, webinars and other activities shares prostate cancer information with all of its participating state prostate cancer organizations, and this material is then disseminated to patients and their families, demonstrating the breadth and depth of our reach. NASPCC also helps equip patients and their families to actively engage in the prostate cancer cause.

THE NASPCC ANNUAL MEETING

The Annual Meeting pulls together leaders in the rapidly developing field of prostate cancer – patients and families, researchers, practitioners, and people interested in the disease – who want to share, learn and lead. The patient community is unique and the contemporary overview in the Take Home Messages from the Annual Meeting allows them to become empowered to do things locally. NASPCC creates support and a forum to enrich and rejuvenate these individuals and state organizations.
JAMES L. GULLEY, MD, PhD
2021-2022 NASPCC Honoree

Dr. James L. Gulley is Chief of the Genitourinary Malignancies Branch of the Center for Cancer Research of the National Cancer Institute; Deputy Director of the Center for Cancer Research; and Senior Investigator, and Director of the Medical Oncology Service, in the CCR Office of the Clinical Director. He is an internationally recognized expert in cancer immunotherapy and has a strong interest in prostate cancer. He works in the well-known Building 10 of NIH. He graduated from Loma Linda University with a PhD in microbiology in 1994 and an MD in 1995, completing a dissertation on tumor immunology. Following a residency in Internal Medicine at Emory University in 1998, he completed a Medical Oncology fellowship at the National Cancer Institute.

Dr. Gulley has developed and runs a number of clinical trials since 1998 involving the use of cancer immunotherapy. His studies involve using cancer vaccines and other agents to modulate the immune response in cancer patients as well as other strategies to fight cancer. Dr. Gulley is an important contributor to first-in-human studies and has investigated PROSTVAC, avelumab, and bintrafusp alfa targeting PDL1 and TGF-beta. He has numerous publications to his credit including, with respect to prostate cancer, a study targeting PSA in metastatic castration-resistant prostate cancer, as well as several publications on PROSTVAC; and he is currently conducting a clinical trial determining the safety and efficacy of PROSTVAC, nivolumab, and ipilumumab in men with localized prostate cancer.

Dr. Gulley has participated and presented at NASPCC’s Annual Meetings for a number of years, always giving us an update on immuno-oncology in prostate cancer. We honor Dr. James J. Gulley this year for his continuing passion and dedication to all patients and for following his dreams of developing and conducting studies to lead to new tools in immuno-oncology, with an exemplary dedication to helping prostate cancer patients, among others.

VINCENT P. LAUDONE, MD
2021-2022 NASPCC Honoree

Dr. Vincent P. Laudone is a board-certified urologic surgeon at Memorial Sloan Kettering Cancer Center in New York, the world’s oldest and largest cancer center and an NCI-designated Comprehensive Cancer Center. Dr. Laudone is Chief of Surgery at Memorial Sloan Kettering’s new Josie Robertson Surgery Center, a special outpatient and short-stay cancer surgery facility in Manhattan.

After graduating from Georgetown University Medical School in 1981, Dr. Laudone completed a residency in Urology at the University of Virginia from 1982-1986, followed by his first Fellowship at Memorial Sloan Kettering in Urologic Oncology from 1986-1988. Dr. Laudone was a Fellow with the American Cancer Society and is a member of Alpha Omega Alpha Medical Society. He has received numerous well-deserved accolades and awards.

As a board-certified urologic surgeon, Dr. Laudone specializes in robotic surgery for people with genitourinary cancers, especially prostate cancer. He has been co-investigator on numerous clinical trials, including on a Study of Gallium-68 after radical prostatectomy.

Dr. Laudone’s concern for patients, his compassion, and his outstanding medical and surgical skills endear him to patients and to those of us who are fortunate enough to work with him. He was a valuable presenter at our celebratory 15th Annual Meeting in October 2019 and contributed substantially to its success. He always offers his assistance in any way possible.

Thank you, Dr. Laudone, for all that you do for patients and all that you do for the National Alliance of State Prostate Cancer Coalitions. We honor you and are so grateful for your contributions to the field of prostate cancer!
David Sauls graduated from HBCU/Delaware State University in 1967 with a Major in Education and a Minor in History. He then served in the U.S. Air Force, earning the Air Force Commendation Medal, the Air Force Good Conduct Medal, and the National Defense medal.

David is a 17-year survivor of Prostate Cancer, having been diagnosed in 2005. He was inducted into the Delaware African-American Sports Hall of Fame in track, that same year. He has been an Executive Board Member of the Delaware Prostate Cancer Coalition, a “Proud Participant in the National Alliance of State Prostate Cancer Coalitions” (“The Prostate Cancer Alliance”), and in fact David is an elected member of the Board of Directors of our Alliance and serves on the Education and Awareness Advisory Committee of the Alliance.

In 2013 David continued his work as a prostate cancer advocate when he served as a Consumer Reviewer for the Scientific Peer Review Panel for the Prostate Cancer Research Program (PCRP) sponsored by the Department of Defense. As a Consumer Reviewer he helped evaluate research applications and helped determine how the $80 million appropriated by Congress for Fiscal Year 2013 would be spent on prostate cancer research. David is also co-author of a DOD-funded Study and Report entitled “Testing a Prostate Cancer Educational Intervention in High-Burden neighborhoods” published in August 2021. That Study showed that “gathering at-risk men for discussions about PCa or other health concerns may increase their PCa knowledge and intention to talk to a doctor about PCa screening”.

David has received numerous honors and awards, including a Community Service Award from the NAACP, Milford branch; and the Founders Award and the Basilus Award from Omega Psi Phi Fraternity, into which he was inducted in 1966. He currently continues to help men and their families by participating in Health Fairs throughout the State of Delaware, and speaking to organizations about Prostate Cancer, using a valuable PowerPoint presentation.

David says that he is proud of his continued dedication to his prostate cancer mission, on which he has been working since 2005. We are also proud of your work, David, AND the spirit with which you help men and their families. Congratulations, prostate cancer warrior **DAVID SAULS**! Our Alliance is proud to bestow upon you the **JAMES WEST SPIRIT AWARD**!
Emmanuel Antonarakis, MD
Professor of Medicine, University of Minnesota
Dr. Emmanuel Antonarakis is Clark Endowed Professor of Medicine at the University of Minnesota. He is a genitourinary medical oncologist with a particular focus on recurrent and advanced prostate cancer. He conducts clinical and translational studies to bring new therapies to patients with prostate cancer, and is especially interested in developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and tumor genomics to inform precision oncology approaches for these patients. He also has an interest in liquid biomarker development, including the clinical validation of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He received his MD from the University of Wales and trained at Johns Hopkins in Baltimore.

Andrew J. Armstrong, MD, MSc
Medical Oncologist,
Duke University School of Medicine
Dr. Andrew J. Armstrong is a board-certified medical oncologist at Duke University with a focus on genitourinary malignancies -- prostate, kidney, bladder, and testicular cancers. He is also a clinical and translational researcher focused on drug development and biomarker studies in prostate and kidney cancer. This research includes prognostic and predictive biomarkers, circulating tumor cell biology, and how cancer spreads (metastasis). He oversees multiple clinical trials of new therapies for patients ranging from new hormonal and chemotherapies to new immunotherapies, and molecularly targeted agents. Dr. Armstrong received his MD from the University of Virginia in 2000 and trained at the University of Pennsylvania and at Johns Hopkins in Baltimore.

Atish Choudhury, MD
Medical Oncologist,
Dana-Farber Cancer Institute
Dr. Choudhury is a medical oncologist and clinical/translational investigator within the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, an Assistant professor of Medicine at Harvard Medical School, and currently serves as a Co-Director of the Prostate Cancer Center at the Dana-Farber/Brigham & Women’s Cancer Center. His research interests include investigation of genetic and epigenetic biomarkers from circulating free DNA from patients with metastatic cancer, biomarker studies from other banked human specimens from patients participating in clinical trials, and clinical investigation in novel therapeutics for genitourinary malignancies.

Jonathan Epstein, MD
Professor of Urologic Pathology, the Johns Hopkins Hospital; Professor of Pathology, Oncology, and Urology, Johns Hopkins School of Medicine
Dr. Jonathan Epstein is the Reinhard Professor of Urologic Pathology and a Professor of Pathology, Oncology, and Urology at Johns Hopkins in Baltimore. He is also the Director of Surgical Pathology at The Johns Hopkins Hospital. He received his MD from Boston University and trained in Anatomic Pathology at Johns Hopkins and in Oncological Pathology at Memorial Sloan Kettering in New York, and has been on the Faculty at Johns Hopkins since 1985. Dr. Epstein has written 7 books and more than 900 articles, and he has been honored with the Koss Medal for Advancement of Urological Pathology, the Arthur Purdy Stout Surgical Pathology Prize and the American Cancer Society Clinical Oncology Career Development Award. Dr. Epstein has one of the largest surgical pathology consulting services in the world with approximately 12,000 cases per year, covering the full range of urologic pathology, and he runs the largest genitourinary pathology fellowship in the world. He is a member of the American Urologic Association, the Arthur Purdy Stout Society of Surgical Pathologists, Former President of the International Society of Urologic Pathology, and one of the Founding Members of the Genitourinary Pathology Society.

James Gulley, MD, PhD, FACP
NIH Lead Prostate Cancer Researcher
Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program, he completed a dissertation on tumor immunology. He completed his residency in Internal Medicine at Emory University in 1998, followed by a Medical Oncology fellowship at the National Cancer Institute (NCI).

Dr. Gulley serves within the Center for Cancer Research (CCR) of the National Cancer Institute as Chief of the Genitourinary Malignancies Branch (GMB), the Director of the Medical Oncology Service (CCR), and also Head of the Immunotherapy Section within the GMB. He has been instrumental in the clinical development a number of therapeutic cancer vaccines. In addition, he was the coordinating PI of an international trial of avelumab that led to regulatory approval and serves as the coordinating PI of the international M7824 bifunctional agent targeting PDL1 and TGF-beta.

Dr. Gulley serves on many national and NIH boards and committees. He has been an investigator on more than 120 clinical trials, authored more than 250 scientific papers or chapters, serves on a number of editorial boards and has made hundreds of presentations at national / international meetings. This will be his third appearance for NASPCC’s Annual Meetings.

continued on next page
Vincent Laudone, MD  
Chief of Surgery, Josie Robertson Surgery Center (JRSC) at Memorial Sloan Kettering Cancer Center  
Dr. Vincent Laudone is Chief of Surgery for the Josie Robertson Surgery Center (JRSC) at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Laudone joined the Urology Service in the Department of Surgery at MSKCC in 2008 and was charged with building the robotic surgical program for the Department. Prior to that he completed a fellowship in Urologic Oncology at MSKCC in 1986 and practiced for twenty years as a founding member of the Connecticut Surgical Group working at Hartford Hospital and the University of Connecticut. In his current role as Chief of Surgery for the JRSC, Dr. Laudone is part of the team that helped design, open, and now run MSKCC’s new unique short-stay ambulatory surgery facility. His clinical focus is on the treatment of men with prostate cancer and his research on improving the effectiveness, efficiency, and quality of care delivered in an ambulatory surgical environment.

Mark Markowski, MD, PhD  
Assistant Professor, John Hopkins University  
Dr. Mark Markowski is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an instructor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and see patients in the genitourinary clinics of both hospitals. He is board-certified in medical oncology and internal medicine by the American Board of Internal Medicine. Dr. Markowski treats numerous types of cancers, with a specialty in prostate cancer.

Dr. Markowski earned his medical degree and PhD in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital. Dr. Markowski is a board member and secretary for the Genito-Urinary Multidisciplinary D.C. Regional Oncology Project (GUMDROP).

Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, and anti-inflammatory agents and cancer incidence. Dr. Markowski is currently conducting research with funding from a Postdoctoral Training Award from the Department of Defense’s Prostate Cancer Research Program, and a Young Investigator Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients and credentialing these treatments for advancement to clinical trials.

Saul Priceman, MD  
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Los Angeles  
Dr. Saul Priceman is an assistant professor in the T Cell Immunotherapy Program at City of Hope and a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate and pancreatic cancer. Dr. Priceman received his B.S. in microbiology at University of California Santa Barbara, and his Ph.D. in molecular and medical pharmacology at University of California Los Angeles. He is a principal investigator on a Prostate Cancer Foundation Young Investigator award, a co-principal investigator on a Prostate Cancer Foundation Challenge Award and a principal investigator on a National Comprehensive Cancer Network Young Investigator award, leading the development of HER2-specific CAR T therapy for metastatic breast cancers and working with his team optimizing new CAR T cell therapies for various other solid cancers. Dr. Priceman is committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of cancer patients. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.

Michael Morris, MD  
Genitourinary Oncologist, Memorial Sloan Kettering Cancer Center  
Dr. Morris is prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He earned his MD from Mount Sinai School of Medicine in New York, and trained in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center, where he was Chief Fellow. Dr. Morris has led numerous clinical trials, and has a particular research focus on targeted therapy for prostate cancer, especially trials that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radioimmunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a strong interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging. In addition, he is the Medical Director of the Prostate Cancer Clinical Consortium, and chairs the GU Committee of the Alliance for Oncology Trials in Oncology, an NCI-funded cooperative group for the conduct of cancer clinical trials.
Ashley Ross, MD, PhD  
Urologic Oncologist, Northwestern Medicine  
Dr. Ross is a urologic oncologist and a surgeon scientist specializing in urology and urologic oncology, and he is a nationally recognized expert in prostate cancer. His research efforts focus on the development, testing and implementation of novel diagnostics and therapeutics to reduce suffering from prostate cancer. Clinically, Dr. Ross performs prostate cancer screening, prostate biopsy (including MRI-fusion biopsy), active surveillance, robotic prostatectomy, open radical prostatectomy, and ablative therapies of the prostate. Prior to joining the Feinberg School of Medicine as Associate Professor of Urology, Dr. Ross served as director of the Johns Hopkins Urology Prostate Cancer Program, the executive medical director of the Mary Crowley Cancer Research Center, and an associate chair of the US Oncology Genitourinary Research Committee. He has been an invited and active participant in NASPCC’s Annual Meeting for several years.

Daniel Y. Song, MD  
Professor, Johns Hopkins Medicine  
Dr. Daniel Song is Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-Director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer. Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy. He received his MD from the Medical College of Georgia, and trained at Johns Hopkins University School of Medicine. Dr. Song is a reviewer and examiner for the American Board of Radiology. He has co-authored consensus guidelines on low-dose-rate brachytherapy, stereotactic body radiation therapy, and image-guided robotic brachytherapy. He also served as Faculty for NASPCC’s 15th Annual Meeting in October 2019.

Mark Vieth  
Senior Vice President, CRD Associates  
Mark D. Vieth, Senior Vice President, joined the firm in 2002 and manages a diverse portfolio of clients in several practice areas, including public health and medical research. Mark currently serves as the coordinator for several national coalitions, including the Defense Health Research Consortium. He has specialized in bringing diverse associations, foundations, institutions of higher education and other stakeholders together to advocate for common objectives. He has helped clients secure federal funding, build new partnerships with federal agencies and mobilize grassroots to advocate for legislation pending in Congress. He also has developed a niche in helping clients who have never interacted with Congress or federal agencies launch sophisticated and focused federal government relations strategies.

Prior to joining CRD Associates, Mark served for 14 years as a professional staff member in the House of Representatives. As Chief of Staff for Congressman Robert A. Borski (D-PA), Mark worked extensively on legislative issues and projects of importance to one of the nation’s major medical research clusters in Philadelphia. Mark is also past President and current Treasurer of the Pennsylvania Society of Washington, D.C. He earned his B.A. in international relations from Syracuse University.
NASPCC would like to thank the following sponsors for their support:

- Dendreon
- Bayer
- Amgen
- Merck
- Lantheus
- Pfizer
- Exact Sciences
- Foundation Medicine
- Clovis Oncology
- Avenda Health
- Myovant Sciences
- Blue Earth Diagnostics
- Sanofi
- Janssen Oncology
- PhRMA
- Promise
- Veru